Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase 2 trial (120 patients planned) comparing progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro) versus pembro. Accrual to the pembro arm was discontinued on the basis of interim analysis (IA—16 wk disease control rate). CP + pembro was tolerable, with progression-free survival similar between arms and median survival and overall response rate higher than those of CP alone (19.8 mo [95% confidence interval or CI: 8.4–41.36] versus 8.9 mo [95% CI: 5.3–12.8] and 47% [95% CI: 24%–71%] versus 19% [95% CI: 5%–42%], respectively). The subsequent phase 3 trial has completed accrual; results are expected in 2023.
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) / Piccirillo, M.C., Chu, Q., Bradbury, P., Tu, W., Coschi, C.H., Grosso, F., Florescu, M., Mencoboni, M., Goffin, J.R., Pagano, M., Ciardiello, F., Cecere, F.L., Vincent, M., Ferrara, R., Dawe, D.E., Hao, D., Lee, C.W., Morabito, A., Gridelli, C., Cavanna, L., et al.. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 18:6(2023), pp. 813-819. [10.1016/j.jtho.2023.02.003]
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
Pagano M.;Ferrara R.;Morabito A.;Perrone F.;
2023-01-01
Abstract
Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase 2 trial (120 patients planned) comparing progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro) versus pembro. Accrual to the pembro arm was discontinued on the basis of interim analysis (IA—16 wk disease control rate). CP + pembro was tolerable, with progression-free survival similar between arms and median survival and overall response rate higher than those of CP alone (19.8 mo [95% confidence interval or CI: 8.4–41.36] versus 8.9 mo [95% CI: 5.3–12.8] and 47% [95% CI: 24%–71%] versus 19% [95% CI: 5%–42%], respectively). The subsequent phase 3 trial has completed accrual; results are expected in 2023.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
